BeOne Medicines Ltd. (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD 180.80
+5.20 (2.96%)
Jul 22, 2025, 9:45 AM HKT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
Collaboration | 30.70M | Log In | Log In | Log In | Log In | Upgrade |
Collaboration Growth | -85.30% | Log In | Log In | Log In | Log In | Upgrade |
Total Product | 3.78B | Log In | Log In | Log In | Log In | Upgrade |
Total Product Growth | 63.91% | Log In | Log In | Log In | Log In | Upgrade |
REVLIMID | 36.03M | Log In | Log In | Log In | Log In | Upgrade |
REVLIMID Growth | - | Log In | Log In | Log In | Log In | Upgrade |
VIDAZA | - | Log In | Log In | Log In | Log In | Upgrade |
VIDAZA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
ABRAXANE | - | Log In | Log In | Log In | Log In | Upgrade |
ABRAXANE Growth | - | Log In | Log In | Log In | Log In | Upgrade |
BRUKINSA | 2.64B | Log In | Log In | Log In | Log In | Upgrade |
BRUKINSA Growth | 88.03% | Log In | Log In | Log In | Log In | Upgrade |
Tislelizumab | 620.84M | Log In | Log In | Log In | Log In | Upgrade |
Tislelizumab Growth | 14.05% | Log In | Log In | Log In | Log In | Upgrade |
XGEVA | 224.40M | Log In | Log In | Log In | Log In | Upgrade |
XGEVA Growth | 116.74% | Log In | Log In | Log In | Log In | Upgrade |
Other Product | 60.04M | Log In | Log In | Log In | Log In | Upgrade |
Other Product Growth | - | Log In | Log In | Log In | Log In | Upgrade |
BLINCYTO | 74.33M | Log In | Log In | Log In | Log In | Upgrade |
BLINCYTO Growth | 45.20% | Log In | Log In | Log In | Log In | Upgrade |
POBEVCY | 53.51M | Log In | Log In | Log In | Log In | Upgrade |
POBEVCY Growth | -13.99% | Log In | Log In | Log In | Log In | Upgrade |
Pamiparib | - | Log In | Log In | Log In | Log In | Upgrade |
KYPROLIS | 66.17M | Log In | Log In | Log In | Log In | Upgrade |
KYPROLIS Growth | 46.60% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
U.S. | 1.96B | Log In | Log In | Log In | Log In | Upgrade |
U.S. Growth | 65.24% | Log In | Log In | Log In | Log In | Upgrade |
China | 1.41B | Log In | Log In | Log In | Log In | Upgrade |
China Growth | 26.89% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 362.63M | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | 73.83% | Log In | Log In | Log In | Log In | Upgrade |
Rest of World | 78.81M | Log In | Log In | Log In | Log In | Upgrade |
Rest of World Growth | 161.15% | Log In | Log In | Log In | Log In | Upgrade |